113975-37-4

Usage

Uses

Used in Pharmaceutical Industry:
1H-Pyrrolo[3,2-c]pyridine,2-methyl-(9CI) is used as a key intermediate compound for the synthesis of pyrrolopyridine derivatives. These derivatives have potential therapeutic applications in treating diseases mediated by prostaglandin D2 (PGD2), a bioactive lipid molecule involved in various physiological processes and pathological conditions.
Used in Drug Development:
The compound serves as a building block for the development of new drugs targeting PGD2-mediated diseases. By modulating the activity of PGD2 receptors, these pyrrolopyridine derivatives may help in the treatment of conditions such as allergic rhinitis, asthma, and other inflammatory disorders.
Used in Chemical Research:
1H-Pyrrolo[3,2-c]pyridine,2-methyl-(9CI) can also be utilized in chemical research for the exploration of novel chemical reactions and the synthesis of other heterocyclic compounds with potential biological activities. This may lead to the discovery of new therapeutic agents and contribute to the advancement of medicinal chemistry.

InChI:InChI=1/C8H8N2/c1-6-4-7-5-9-3-2-8(7)10-6/h2-5,10H,1H3

Upstream product

• 1279863-30-7 1-tosyl-1H-pyrrolo[3,2-c]pyridine 
• 271-34-1 5-azaindole 
• 98400-69-2 N-(4-pyridyl) t-butyl carbamate 
• 504-24-5 4-aminopyridine 
• 1437769-26-0 (E)-3-(2-nitroprop-1-enyl)pyridine 
• 449173-27-7 4-amino-3-(1-propynyl)pyridine 
• 13534-98-0 3-bromopyridin-4-amine 
• 67-64-1 acetone 
• 211029-67-3 (3-iodo-pyridin-4-yl)-carbamic acid tert-butyl ester 
• 211029-77-5 tert-butyl 2-methyl-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 108-99-6 3-Methylpyridine 
• 1990-90-5 4-amino-3-methylpyridine 
• 113975-33-0 2,2-dimethyl-N-(3-iodo-4-pyridinyl)propanamide 
• 70298-89-4 4-N-pivaloylaminopyridine 

Downstream Products

• 875415-43-3 5-(5-fluoro-2-methoxyphenyl)-2,3-dimethyl-3-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)hexan-3-ol 
• 871327-71-8 [3-(4-chloro-phenylsulfanyl)-2-methyl-pyrrolo[3,2-c]pyridin-1-yl]-acetic acid ethyl ester 
• 871327-73-0 [3-(4-chloro-phenylsulfonyl)-2-methyl-pyrrolo[3,2-c]pyridin-1-yl]-acetic acid ethyl ester 
• 871327-75-2 [3-(4-chloro-phenylsulfonyl)-2-methyl-5-oxy-pyrrolo[3,2-c]pyridin-1-yl]-acetic acid ethyl ester 
• 875415-40-0 2-Cyclopropyl-4-(5-fluoro-2-methylphenyl)-4-methyl-1-(1H-pyrrolo[3,2-c]pyridin-2-yl)pentan-2-ol 
• 1348152-65-7 C₂₄H₃₁FN₂O 
• 875415-35-3 2-Cyclopropyl-4-(5-fluoro-2-methoxyphenyl)-4-methyl-1-(1H-pyrrolo[3,2-c]pyridin-2-yl)pentan-2-ol 
• 875415-68-2 5-(5-Fluoro-2-methoxyphenyl)-2,2,5-trimethyl-3-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)hexan-3-ol 
• 871327-70-7 3-(4-chloro-phenylsulfanyl)-2-methyl-1H-pyrrolo[3,2-c]pyridine 

Relevant academic research and scientific papers

Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity

Kallikrein-related peptidase 6 (KLK6) is a secreted serine protease that belongs to the family of tissue kallikreins (KLKs). Many KLKs are investigated as potential biomarkers for cancer as well as therapeutic drug targets for a number of pathologies. KLK6, in particular, has been implicated in neurodegenerative diseases and cancer, but target validation has been hampered by a lack of selective inhibitors. This work introduces a class of depsipeptidic KLK6 inhibitors, discovered via high-throughput screening, which were found to function as substrate mimics that transiently acylate the catalytic serine of KLK6. Detailed structure-activity relationship studies, aided by in silico modeling, uncovered strict structural requirements for potency, stability, and acyl-enzyme complex half-life. An optimized scaffold, DKFZ-251, demonstrated good selectivity for KLK6 compared to other KLKs, and on-target activity in a cellular assay. Moreover, DKFZ-633, an inhibitor-derived activity-based probe, could be used to pull down active endogenous KLK6.

Synthesis of Indoles by Palladium-Catalyzed Reductive Cyclization of β-Nitrostyrenes with Carbon Monoxide as the Reductant

An efficient catalytic cyclization of β-nitrostyrenes to indoles was developed. The reaction was applied to the synthesis of 3-arylindoles and 2-alkylindoles. Given that in the latter case the starting β-nitrostyrenes can be easily obtained by a Henry reaction, the present method allows indoles to be obtained in a two-step sequence starting from cheap reactants.

PROTEASOME ACTIVITY ENHANCING COMPOUNDS

The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, the methods of synthesis of the compouds of interest, and to methods for the treatment of a condition associated with a dysfunction in proteostasis, such as cancer, inflammatory conditions, neurodegeneration, metabolic conditions, comprising administering an effective amount of a compound of the invention.

A convenient palladium-catalyzed azaindole synthesis

A one-pot protocol is described which allows direct access to azaindoles from amino-halopyridines and ketones.

A convenient palladium-catalyzed azaindole synthesis

A one-pot protocol is described which allows direct access to azaindoles from amino-halopyridines and ketones.

FAAH INHIBITORS

The present disclosure relates to compounds useful as inhibitors of the enzyme Fatty Acid Amide Hydrolase (FAAH). The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the com

PYRROLOPYRIDINE DERIVATIVES AND USE THEREOF FOR TREATING DISEASES MEDIATED BY PROSTAGLANDIN D2 (PGD2)

Compounds of formula (Ia) or (Ib): or pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs thereof are useful in the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO

Compounds of Formula (IA), IB), IC), and (ID) wherein R1, R2, R3, R4, R5, and R6 are as respectively defined herein for Formula (IA), (IB), (IC), and (ID), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

A general and efficient synthesis of azaindoles and diazaindoles

The DBU-mediated cyclization of ortho-(Boc-amino)alkynyl pyridines, -pyridazines, -pyrimidines and -pyrazines efficiently generates azaindoles and diazaindoles, respectively. The reaction proceeds under mild conditions and in high yields. A variety of fun

Transition metal catalyzed synthesis of 5-azaindoles

In an effort to develop synthetic procedures for the preparation of 2- substituted 5-azaindoles, the synthesis and cyclization reactions of acetylenic aminopyridines was explored. A novel method for the synthesis of 2-substituted 5-azaindoles via a transi